Efficacy and safety of botulinum toxin type a in the treatment of glabellar lines: A meta-analysis of randomized, placebo-controlled, double-blind trials

Plastic and Reconstructive Surgery

Volumn 136, Issue 3, 2015, Pages 310e-318e

  Guo, Yu ^a   Lu, Yongzhou ^a   Liu, Tianyi ^a   Zhou, Yiqun ^a   Yang, Ping ^a   Zhu, Jingjing ^a   Chen, Liang ^a   Yang, Qingjian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

CUTANEOUS PARAMETERS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESTHETIC SURGERY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL;

BOTULINUM TOXINS, TYPE A; COSMETIC TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MODELS, STATISTICAL; NEUROMUSCULAR AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN AGING;

EID: 84940976493     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0000000000001544     Document Type: Article

References (34)

1. Carruthers JD, Carruthers JA., Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992 18 17 21
2. Carruthers J, Carruthers JA., The use of botulinum toxin to treat glabellar frown lines and other facial wrinkles. Cosmet Dermatol 1994 7 11 15
3. Carruthers A, Carruthers J., Botulinum toxin products overview. Skin Therapy Lett 2008 13 1 4
4. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J., A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004 51 223 233
5. Carruthers A, Carruthers J., Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005 31 1297 1303
6. Carruthers A, Carruthers J, Said S., Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005 31 414 422
7. Carruthers JA, Lowe NJ, Menter MA, Botox Glabellar Lines I Study Group A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002 46 840 849
8. Lowe P, Patnaik R, Lowe N., Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized study. J Am Acad Dermatol 2006 55 975 980
9. Monheit G, Carruthers A, Brandt F, Rand R., A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg 2007 33 S51 S59
10. Naumann M, Jankovic J., Safety of botulinum toxin type A: A systematic review and meta-Analysis. Curr Med Res Opin 2004 20 981 990
11. Kaltreider SA, Kennedy RH, Woog JJ, American Academy of Ophthalmology; Ophthalmic Technology Assessment Committee Oculoplastics Panel Cosmetic oculofacial applications of botulinum toxin: A report by the American Academy of Ophthalmology. Ophthalmology 2005 112 1159 1167
12. Brin MF, Boodhoo TI, Pogoda JM, Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-Analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol 2009 61 961 970.e1
13. Gadhia K, Walmsley AD., Facial aesthetics: Is botulinum toxin treatment effective and safe? A systematic review of randomized controlled trials. Br Dent J 2009 207 E9 discussion 216-217
14. Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E., Current processes of the US Preventive Services Task Force: Refining evidence-based recommendation development. Ann Intern Med 2007 147 117 122
15. Hanke CW, Narins RS, Brandt F, A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg 2013 39 891 899
16. Carruthers A, Carruthers J, Coleman WP III, Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg 2013 39 551 558
17. Wu Y, Zhao G, Li H, Botulinum toxin type A for the treatment of glabellar lines in Chinese: A double-blind, randomized, placebo-controlled study. Dermatol Surg 2010 36 102 108
18. Harii K, Kawashima M., A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg 2008 32 724 730
19. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N., Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003 112 1089 1098
20. Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW., Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double-blind, randomized, placebo-controlled study. Dermatol Surg 2007 33 S2 S9
21. Carruthers A, Carruthers J, Lei X, Pogoda JM, Eadie N, Brin MF., OnabotulinumtoxinA treatment of mild glabellar lines in repose. Dermatol Surg 2010 36 Suppl 4 2168 2171
22. Kane MA, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB., Evaluation of variable-dose treatment with a new us botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: Results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009 124 1619 1629
23. Brandt F, Swanson N, Baumann L, Huber B., Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: Efficacy and safety. Dermatol Surg 2009 35 1893 1901
24. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W., Efficacy and safety of 3-And 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006 142 320 326
25. Rubin M, Dover J, Maas C, Nestor M., An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J 2009 29 Suppl S50 S56
26. Jones D, Carruthers J, Narins RS, Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: A post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials. Dermatol Surg 2014 40 776 785
27. Alimohammadi M, Andersson M, Punga AR., Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: A double-blind, placebo-controlled, randomized study. Acta Derm Venereol 2014 94 32 37
28. Phadke CP, Davidson C, Ismail F, Boulias C., The effect of neural lesion type on botulinum toxin dosage: A retrospective chart review. PM R 2014 6 406 411
29. Nguyen AT, Ahmad J, Fagien S, Rohrich RJ., Cosmetic medicine: Facial resurfacing and injectables. Plast Reconstr Surg 2012 129 142e 153e
30. Nalysnyk L, Papapetropoulos S, Rotella P, Simeone JC, Alter KE, Esquenazi A., OnabotulinumtoxinA muscle injection patterns in adult spasticity: A systematic literature review. BMC Neurol 2013 13 118
31. Fortuna R, Horisberger M, Vaz MA, Van der Marel R, Herzog W., The effects of electrical stimulation exercise on muscles injected with botulinum toxin type-A (Botox). J Biomech 2013 46 36 42
32. Tan CL, Andrews MR, Kwok JC, Kindlin-1 enhances axon growth on inhibitory chondroitin sulfate proteoglycans and promotes sensory axon regeneration. J Neurosci 2012 32 7325 7335
33. Fabregat G, De Andrés J, Villanueva-Pérez VL, Asensio-Samper JM., Subcutaneous and perineural botulinum toxin type a for neuropathic pain: A descriptive review. Clin J Pain 2013 29 1006 1012
34. Cavallini M, Cirillo P, Fundarò SP, Safety of botulinum toxin A in aesthetic treatments: A systematic review of clinical studies. Dermatol Surg 2014 40 525 536